The lung Cancer Screening Market size was valued at USD 2.36 Billion in 2022 and the total Lung Cancer Screening revenue is expected to grow at a CAGR of 8.32% from 2023 to 2029, reaching nearly USD 4.13 Billion.Lung Cancer Screening Market Overview:
Lung cancer is the biggest cause of cancer-related mortality globally. Targeted lung cancer screening with low-dose computed tomography (LDCT) has the potential to move lung cancer diagnosis to earlier stages when the prognosis is significantly better. As a result, targeted screening has the potential to greatly enhance lung cancer survivors' survival rates and quality of life. The ultimate goal of lung cancer screening programs is to minimize mortality by detecting cancer earlier. To do this, screening programs must target people who are most likely to benefit from lung cancer screening. This necessitates identifying the target demographic in each location based on current evidence of recognized risk factors. A vital initial step for any screening program is to define adequate and adaptive screening eligibility criteria. While smoking is a major risk factor for lung cancer, there is a rising understanding of the impact of other variables as well. Most clinical studies conducted to date have focused LDCT screening on persons within a given age range who smoke heavily and those who used to smoke heavily. The lung cancer screening market is growing since the prevalence of this form of cancer has increased due to an increase in the smoking population, technical advancements in screenings, and increased government assistance and initiatives for early diagnosis of cases. Besides that, strategic collaborations and updated screening recommendations and recommendations are expected to boost the lung cancer screening market growth during the forecast period. For example, in 2019, Genentech and Roche collaborated to investigate biomarker screening for lung cancer therapy and diagnosis. This genome-based testing, according to the businesses, might soon replace invasive tissue biopsies of the lungs. Meanwhile, the factors such as a rapid increase in doctors' use of low-dose computed tomography for lung cancer screening are expected to generate lucrative revenue for the lung cancer screening market growth. Likewise, increased awareness of innovative and affordable lung cancer screening methods in developing countries such as India and China helps to market growth. A few market participants are pursuing inorganic strategies, such as partnerships with healthcare organizations, in order to raise broad public awareness regarding lung cancer. Nuance Communications, Inc., for example, teamed with Baptist Health South Florida's Miami Cancer Institute (MCI) to build a lung cancer screening program that includes imaging tests for early detection and successful disease treatment. However, the high cost of screening is expected to restrict the market's growth during the forecast period. In addition, chest X-rays and computed tomography expose the chest to radiation, which causes health problems for the patient. These factors are expected to restrain the growth of the lung cancer screening market.To know about the Research Methodology :- Request Free Sample Report
Lung Cancer Screening Market Dynamics:
Increasing R&D activities and product approvals An increased focus on research and development activities of lung cancer diagnostic and screening tests is one of the major factors driving the lung cancer screening market growth. For example, in April 2020, researchers at the Massachusetts Institute of Technology (MIT) developed a nanoparticle-based method for early lung cancer detection via a simple urine test. The method identifies biomarkers produced by peptide-coated nanoparticles interacting with disease-associated proteases in the tumor microenvironment. Experiments in two distinct lung cancer mouse models revealed that the urine test may identify tumors as tiny as 2.8 mm. The researchers expect that this noninvasive diagnosis approach would lower the number of false positives associated with a current test method and allow them to discover more cancers in the early stages of illness. In addition, growing market players' adoption of inorganic growth strategies such as mergers and acquisitions is expected to boost the global lung cancer screening market growth during the forecast period. Amgen, for example, announced significant agreements with top diagnostic firms Guardant Health, Inc. and QIAGEN N.V. in January 2020 to develop blood and tissue-based companion diagnostics (CDx) for the experimental cancer drug AMG 510, respectively. AMG 510 is the first KRASG12C inhibitor to enter clinical trials for the treatment of several tumor types. In human cancer, KRAS G12C is one of the most commonly mutated oncogenes. Both firms' collaborations would first focus on CDx testing for non-small cell lung cancer (NSCLC). Growing prevalence of lung cancer and cigarettes consumption The rapidly growing global prevalence of cancer, increasing healthcare costs, and increased diagnosis provide a huge patient pool undergoing screening methods. These are the variables that are expected to drive the lung cancer screening market growth during the forecast period. According to the American Society of Clinical Oncology (2020), lung cancer is the second most frequent disease in both men and women, affecting about 235,000 persons in the United States in 2020. Similarly, according to Globocan (Global Cancer Observatory), 64,804 new cases of cancer is reported in Germany in 2020. According to the research, over 50,000 people died in the country from lung cancer, making it the leading cause of mortality among cancers. The global burden of this disease is increasing due to factors such as obesity, smoking, and lifestyle changes. Smoking and vaping are expected to raise the overall population's risk of lung cancer. The increase in incidence is expected to raise the global need for effective screening tests and remedies. As a result, the revenue growth of the lung cancer screening market is expected to increase during the forecast period.High Cost of lung cancer screening tests The high cost of screening makes it unaffordable for the entire population, particularly the low-income to do lung cancer screening tests. Besides that, a lack of screening knowledge in undeveloped countries is expected to hamper lung cancer screening market growth. In the United States, for example, the typical cost of a CT scan is over USD 300, and insurance companies only cover people who are at high risk of getting lung cancer. Additionally, the scarcity of radiologists, radiology technicians, and laboratory practitioners in emerging and underdeveloped countries is expected to restrict the number of screening tests performed throughout the forecast period. As a result, all of the aforementioned constraints restrict the adoption of lung screening solutions and are expected to hamper the market growth in the forecast period. Technological Advancements in Screening Techniques Advanced products are being developed by major manufacturers in the medical device industry. To meet consumers' unmet demands, the screening and diagnostic industry are undergoing major technical developments. Major market players, as well as research-based start-ups, are seeking financing for research and clinical testing of lung cancer screening technologies. Growing incidence and prevalence are driving market participants to provide efficient and cost-effective diagnostic and screening methods. For example, in September 2020, researchers from the University of Otago carried out a study on the detection of lung cancer using low-dose computed tomography (LDCT). The study was published in the medical journal BMJ Open, and it utilized scientific modeling to evaluate the advantages of low-cost LDCT screening. However, the rapid growth of the medical device business is driving established market leaders and local firms to broaden their product offerings. This is driving fierce rivalry among market participants to acquire a competitive advantage over others by developing novel solutions for categories such as lung screening. As a result, the rising technological advancements in screening techniques offer lucrative growth opportunities for the lung cancer screening market growth.
Lung Cancer Screening Market Segment Analysis:
Based on Cancer Type, the Non-small Cell Lung Cancer (NSCLC) segment dominated the global lung cancer screening market with the highest market share of 78% in 2022. This segment is further expected to maintain its dominance with the highest market share of 85% at the end of the forecast period. Non-small cell lung cancer (NSCLC) is the most common type of cancer, accounting for 85% of lung cancer occurrences. However, NSCLC subtypes include large cell carcinoma, adenocarcinoma, squamous cell carcinoma, and other less common types of NSCLC. Increased screening awareness in developed and developing countries, along with an increase in NSCLC incidence globally, is expected to drive segment growth over the forecast period. As a result, during the forecast period, the segment is expected to grow at an 8.24% CAGR. According to the American Cancer Society, approximately 84% of all lung malignancies are non-small cell, while 13% are SCLC. Meanwhile, according to Cancer.Net, the five-year survival rate for NSCLC is 24%, compared to 6% for SCLC.The small cell lung cancer segment is expected to hold a significant market share of the lung cancer screening market during the forecast period. The rising incidence of the disease, together with increased activities by government and non-profit organizations to promote early screening and diagnosis, are expected to drive the segment's growth. Based on Diagnosis Type, the Low Dose Spiral CT Scan segment held the largest market share of about 74% in 2022. The segment is expected to dominate the lung cancer screening market at the end of the forecast period. The favorable reimbursement regulations for cancer screening and the increasing adoption of low-dose spiral CT scan in the screening of this type of cancer is expected to drive the segment growth during the forecast period. Additionally, rising awareness regarding the mortality advantages of low-dose spiral CT scan screening is expected to influence market growth throughout the forecast period. The National Cancer Institute's Division of Cancer Prevention, for example, performed the National Lung Screening Trial at 33 screening facilities across the United States with 53,456 participants. According to the trial, screening with low-dose CT decreased mortality by 20%. Similarly, in Europe, trials such as the Dutch-Belgian Randomized Lung Cancer Screening Trial (NELSON study) and the U.K. Lung Cancer Screening (UKLS) indicated the benefits of low-dose spiral CT scans over older screening techniques such as chest X-rays.
The U.S. market dominated the North American lung cancer screening market in 2022 Adult lung cancer is the main cause of cancer mortality in the United States. Lung cancer claimed the lives of 210,828 people in 2018 and died 157,423 people. Some populations have a greater rate of new cases and deaths from lung cancer than others. Rising governmental initiatives driving the growth of the lung cancer screening market during the forecast period. For instance, The US Preventive Services Task Force national health guidelines for lung cancer screening recommend that people who smoke should also receive smoking cessation support during screening. In addition, Professional organizations such as the American Thoracic Society and the American College of Chest Physicians have issued recommendations for developing comprehensive lung cancer screening, but it has previously been reported that sites differ in their readiness to provide smoking cessation services. In its implementation guide for lung cancer screening, the American Thoracic Society now includes an entire section dedicated to smoking cessation tools. Telephone-based help, for example, has also been proven to be beneficial. The European market is expected to grow at a CAGR of 7.98% and hold the second-highest position in the global lung cancer screening market at the end of the forecast period. The presence of a well-established healthcare market in European countries, the increasing prevalence of this condition, the growing smoking population, and the availability of enhanced screening instruments in healthcare facilities are expected to increase market growth. According to the European Society for Medical Oncology, 2020 statistics, smoking was responsible for NSCLC in almost 85% of all patients. Lung cancer is the third most frequent cancer in Europe, yet it is still the leading cause of death. With the exception of lung cancer, which is expected to rise in women, recent European cancer mortality estimates show a downward trend in most cancer types in both sexes due to improved prevention and treatment. Tobacco smoking is the single most preventable risk factor for lung cancer mortality globally. In the short term, encouraging current smokers to quit smoking and screening high-risk current and former smokers is expected to have a greater impact on lowering tobacco-related mortality and increasing market growth. The Asia-pacific market held a significant market share of the market in 2022 and is expected to grow at a considerable CAGR during the forecast period. The high prevalence of smoking and tobacco use among the Asian population led market participants and government institutions to support the adoption of screening equipment, and national government initiatives to develop a robust framework for lung cancer screening boosted the market growth. In addition, the introduction of innovative lung cancer screening tests by leading companies drives the growth of the lung cancer screening market during the forecast period. For example, in February 2022, AnPac Bio-Medical Science Co., Ltd, a biotechnology company focused on early cancer screening and detection with operations in China and the United States, announced that on January 25, 2021, the National Medical Products Administration, China's medical product regulatory authority, approved AnPac Bio to begin registration testing of its Class III lung cancer auxiliary diagnosis medical device at a designated medical device testing laboratory.
The Latin American market is expected to hold a comparatively moderate share of the global market due to the lack of awareness and restrictions on access to screening. The strong emphasis on hospital and healthcare infrastructure development in the Gulf region, rising government investments for the development of healthcare facilities, and the introduction of private players in the Middle East and Africa's healthcare sector are expected to provide a favorable environment for market growth during the forecast period. Latin America is expected to hold a comparatively moderate market share of the global lung cancer screening market due to the lack of awareness and limited access to screening. The increasing focus on hospital and healthcare infrastructure development in the Gulf region, increasing government investments for the development of healthcare facilities, and the entry of private players in the Middle East and Africa's healthcare sector are expected to provide favorable conditions for the lung cancer screening market growth during the forecast period.
Lung Cancer Screening Market Scope: Inquiry Before Buying
Lung Cancer Screening Market Report Coverage Details Base Year: 2022 Forecast Period: 2023-2029 Historical Data: 2017 to 2022 Market Size in 2022: US $ 2.36 Billion. Forecast Period 2023 to 2029 CAGR: 8.32% Market Size in 2029: US $ 4.13 Billion. Segments Covered: by Cancer Type 1. Non-small Cell Lung Cancer (NSCLC) 2. Small Cell Lung Cancer by Diagnosis Type 1. Low Dose Spiral CT Scan 2. Chest X-ray by Age Group 1. 50 and Older 2. Below 50 by End-User 1. Hospitals & Clinics 2. Diagnostic Centres 3. Other Lung Cancer Screening Market, by Region
North America (United States, Canada and Mexico) Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe) Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC) Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A) South America (Brazil, Argentina Rest of South America)Lung Cancer Screening Market, Key Players are
1. GE Healthcare (United States) 2. PenRad Technologies, Inc. (United States) 3. NanoString, Myriad Genetics Inc. (United States) 4. OncoCyte (United States) 5. Biodesix (United States) 6. Broncus (United States) 7. Abbott (United States) 8. Illumina, Inc., (United States) 9. Thermo Fischer Scientific (United States) 10. Medtronic (United States) 11. Nuance Communications, Inc. (United States) 12. Riverain Tech (United States) 13. 20/20 Gene Systems (United States) 14. Danaher Corporation (United States) 15. NeoGenomics (United States) 16. Eon Health (United States) 17. Siemens Healthineers AG (Germany) 18. Agilent Technologies, Inc., AstraZeneca (United Kingdom) 19. Insight Genetics (United Kingdom) 20. Inivata (United Kingdom) 21. Oncimmune (United Kingdom) 22. Koninklijke Philips N.V. (The Netherlands) 23. QIAGEN (The Netherlands) 24. Quest Diagnostics Incorporated (The Netherlands) 25. F. Hoffmann-La Roche Ltd. (Switzerland) 26. Janssen Pharmaceuticals, Inc. (Belgium) 27. Sanofi, (France) 28. Canon Medical Systems Corporation (Japan) 29. FUJIFILM Holdings Corporation (Japan) 30. VisionGate (India) 31. Integrated Diagnostics (India) 32. Volpara Solutions Limited. (New Zealand) FAQs: 1. What are the growth drivers for the Lung Cancer Screening market? Ans. An increased focus on research and development activities of lung cancer diagnostic and screening tests, growing market players' adoption of inorganic growth strategies such as mergers and acquisitions, rapidly growing global prevalence of cancer, increasing healthcare costs, and increased diagnosis provide a huge patient pool undergoing screening methods are expected to be the major driver for the Lung Cancer Screening market. 2. What is the major restraint for the Lung Cancer Screening market growth? Ans. The high costs of lung cancer screening tests, chest X-rays, and computed tomography expose the chest to radiation, which causes health problems for the patient are expected to be the major restraining factor for the Lung Cancer Screening market growth. 3. Which region is expected to lead the global Lung Cancer Screening market during the forecast period? Ans. The North American market is expected to lead the global Lung Cancer Screening market during the forecast period due to the rapidly increasing cases of lung cancer, strong implementation of screening programs, increased adoption of advanced technological solutions, and rising government initiatives to the adoption of lung cancer screening solutions. 4. What is the projected market size & growth rate of the Lung Cancer Screening Market? Ans. The lung Cancer Screening Market size was valued at USD 2.36 Billion in 2022 and the total Lung Cancer Screening revenue is expected to grow at a CAGR of 8.32% from 2023 to 2029, reaching nearly USD 4.13 Billion. 5. What segments are covered in the Lung Cancer Screening Market report? Ans. The segments covered in the Lung Cancer Screening market report are Cancer Type, Diagnosis Type, Age Group, End-user, and Region.
1. Lung Cancer Screening Market Introduction 1.1. Study Assumption and Market Definition 1.2. Scope of the Study 1.3. Executive Summary 2. Lung Cancer Screening Market: Dynamics 2.1. Lung Cancer Screening Market Trends by Region 2.1.1. North America Lung Cancer Screening Market Trends 2.1.2. Europe Lung Cancer Screening Market Trends 2.1.3. Asia Pacific Lung Cancer Screening Market Trends 2.1.4. Middle East and Africa Lung Cancer Screening Market Trends 2.1.5. South America Lung Cancer Screening Market Trends 2.2. Lung Cancer Screening Market Dynamics by Region 2.2.1. North America 2.2.1.1. North America Lung Cancer Screening Market Drivers 2.2.1.2. North America Lung Cancer Screening Market Restraints 2.2.1.3. North America Lung Cancer Screening Market Opportunities 2.2.1.4. North America Lung Cancer Screening Market Challenges 2.2.2. Europe 2.2.2.1. Europe Lung Cancer Screening Market Drivers 2.2.2.2. Europe Lung Cancer Screening Market Restraints 2.2.2.3. Europe Lung Cancer Screening Market Opportunities 2.2.2.4. Europe Lung Cancer Screening Market Challenges 2.2.3. Asia Pacific 2.2.3.1. Asia Pacific Lung Cancer Screening Market Drivers 2.2.3.2. Asia Pacific Lung Cancer Screening Market Restraints 2.2.3.3. Asia Pacific Lung Cancer Screening Market Opportunities 2.2.3.4. Asia Pacific Lung Cancer Screening Market Challenges 2.2.4. Middle East and Africa 2.2.4.1. Middle East and Africa Lung Cancer Screening Market Drivers 2.2.4.2. Middle East and Africa Lung Cancer Screening Market Restraints 2.2.4.3. Middle East and Africa Lung Cancer Screening Market Opportunities 2.2.4.4. Middle East and Africa Lung Cancer Screening Market Challenges 2.2.5. South America 2.2.5.1. South America Lung Cancer Screening Market Drivers 2.2.5.2. South America Lung Cancer Screening Market Restraints 2.2.5.3. South America Lung Cancer Screening Market Opportunities 2.2.5.4. South America Lung Cancer Screening Market Challenges 2.3. PORTER’s Five Forces Analysis 2.4. PESTLE Analysis 2.5. Technology Roadmap 2.6. Regulatory Landscape by Region 2.6.1. North America 2.6.2. Europe 2.6.3. Asia Pacific 2.6.4. Middle East and Africa 2.6.5. South America 2.7. Key Opinion Leader Analysis For Lung Cancer Screening Industry 2.8. Analysis of Government Schemes and Initiatives For Lung Cancer Screening Industry 2.9. Lung Cancer Screening Market Trade Analysis 2.10. The Global Pandemic Impact on Lung Cancer Screening Market 3. Lung Cancer Screening Market: Global Market Size and Forecast by Segmentation by Demand and Supply Side (by Value in USD Million) 2022-2029 3.1. Lung Cancer Screening Market Size and Forecast, by Cancer Type (2022-2029) 3.1.1. Non-small Cell Lung Cancer (NSCLC) 3.1.2. Small Cell Lung Cancer 3.2. Lung Cancer Screening Market Size and Forecast, by Diagnosis Type (2022-2029) 3.2.1. Low Dose Spiral CT Scan 3.2.2. Chest X-ray 3.3. Lung Cancer Screening Market Size and Forecast, by Age Group (2022-2029) 3.3.1. 50 and Older 3.3.2. Below 50 3.4. Lung Cancer Screening Market Size and Forecast, by End-User (2022-2029) 3.4.1. Hospitals & Clinics 3.4.2. Diagnostic Centres 3.4.3. Other 3.5. Lung Cancer Screening Market Size and Forecast, by Region (2022-2029) 3.5.1. North America 3.5.2. Europe 3.5.3. Asia Pacific 3.5.4. Middle East and Africa 3.5.5. South America 4. North America Lung Cancer Screening Market Size and Forecast by Segmentation (by Value in USD Million) 2022-2029 4.1. North America Lung Cancer Screening Market Size and Forecast, by Cancer Type (2022-2029) 4.1.1. Non-small Cell Lung Cancer (NSCLC) 4.1.2. Small Cell Lung Cancer 4.2. North America Lung Cancer Screening Market Size and Forecast, by Diagnosis Type (2022-2029) 4.2.1. Low Dose Spiral CT Scan 4.2.2. Chest X-ray 4.3. North America Lung Cancer Screening Market Size and Forecast, by Age Group (2022-2029) 4.3.1. 50 and Older 4.3.2. Below 50 4.4. North America Lung Cancer Screening Market Size and Forecast, by End-User (2022-2029) 4.4.1. Hospitals & Clinics 4.4.2. Diagnostic Centres 4.4.3. Other 4.7. North America Lung Cancer Screening Market Size and Forecast, by Country (2022-2029) 4.5.1. United States 4.5.1.1. United States Lung Cancer Screening Market Size and Forecast, by Cancer Type (2022-2029) 4.5.1.1.1. Non-small Cell Lung Cancer (NSCLC) 4.5.1.1.2. Small Cell Lung Cancer 4.5.1.2. United States Lung Cancer Screening Market Size and Forecast, by Diagnosis Type (2022-2029) 4.5.1.2.1. Low Dose Spiral CT Scan 4.5.1.2.2. Chest X-ray 4.5.1.3. United States Lung Cancer Screening Market Size and Forecast, by Age Group (2022-2029) 4.5.1.3.1. 50 and Older 4.5.1.3.2. Below 50 4.5.1.4. United States Lung Cancer Screening Market Size and Forecast, by End-User (2022-2029) 4.5.1.4.1. Hospitals & Clinics 4.5.1.4.2. Diagnostic Centres 4.5.1.4.3. Other 4.5.2. Canada 4.5.2.1. Canada Lung Cancer Screening Market Size and Forecast, by Cancer Type (2022-2029) 4.5.2.1.1. Non-small Cell Lung Cancer (NSCLC) 4.5.2.1.2. Small Cell Lung Cancer 4.5.2.2. Canada Lung Cancer Screening Market Size and Forecast, by Diagnosis Type (2022-2029) 4.5.2.2.1. Low Dose Spiral CT Scan 4.5.2.2.2. Chest X-ray 4.5.2.3. Canada Lung Cancer Screening Market Size and Forecast, by Age Group (2022-2029) 4.5.2.3.1. 50 and Older 4.5.2.3.2. Below 50 4.5.2.4. Canada Lung Cancer Screening Market Size and Forecast, by End-User (2022-2029) 4.5.2.4.1. Hospitals & Clinics 4.5.2.4.2. Diagnostic Centres 4.5.2.4.3. Other 4.5.3. Mexico 4.5.3.1. Mexico Lung Cancer Screening Market Size and Forecast, by Cancer Type (2022-2029) 4.5.3.1.1. Non-small Cell Lung Cancer (NSCLC) 4.5.3.1.2. Small Cell Lung Cancer 4.5.3.2. Mexico Lung Cancer Screening Market Size and Forecast, by Diagnosis Type (2022-2029) 4.5.3.2.1. Low Dose Spiral CT Scan 4.5.3.2.2. Chest X-ray 4.5.3.3. Mexico Lung Cancer Screening Market Size and Forecast, by Age Group (2022-2029) 4.5.3.3.1. 50 and Older 4.5.3.3.2. Below 50 4.5.3.4. Mexico Lung Cancer Screening Market Size and Forecast, by End-User (2022-2029) 4.5.3.4.1. Hospitals & Clinics 4.5.3.4.2. Diagnostic Centres 4.5.3.4.3. Other 5. Europe Lung Cancer Screening Market Size and Forecast by Segmentation (by Value in USD Million) 2022-2029 5.1. Europe Lung Cancer Screening Market Size and Forecast, by Cancer Type (2022-2029) 5.2. Europe Lung Cancer Screening Market Size and Forecast, by Diagnosis Type (2022-2029) 5.3. Europe Lung Cancer Screening Market Size and Forecast, by Age Group (2022-2029) 5.4. Europe Lung Cancer Screening Market Size and Forecast, by End-User (2022-2029) 5.5. Europe Lung Cancer Screening Market Size and Forecast, by Country (2022-2029) 5.5.1. United Kingdom 5.5.1.1. United Kingdom Lung Cancer Screening Market Size and Forecast, by Cancer Type (2022-2029) 5.5.1.2. United Kingdom Lung Cancer Screening Market Size and Forecast, by Diagnosis Type (2022-2029) 5.5.1.3. United Kingdom Lung Cancer Screening Market Size and Forecast, by Age Group(2022-2029) 5.5.1.4. United Kingdom Lung Cancer Screening Market Size and Forecast, by End-User (2022-2029) 5.5.2. France 5.5.2.1. France Lung Cancer Screening Market Size and Forecast, by Cancer Type (2022-2029) 5.5.2.2. France Lung Cancer Screening Market Size and Forecast, by Diagnosis Type (2022-2029) 5.5.2.3. France Lung Cancer Screening Market Size and Forecast, by Age Group(2022-2029) 5.5.2.4. France Lung Cancer Screening Market Size and Forecast, by End-User (2022-2029) 5.5.3. Germany 5.5.3.1. Germany Lung Cancer Screening Market Size and Forecast, by Cancer Type (2022-2029) 5.5.3.2. Germany Lung Cancer Screening Market Size and Forecast, by Diagnosis Type (2022-2029) 5.5.3.3. Germany Lung Cancer Screening Market Size and Forecast, by Age Group (2022-2029) 5.5.3.4. Germany Lung Cancer Screening Market Size and Forecast, by End-User (2022-2029) 5.5.4. Italy 5.5.4.1. Italy Lung Cancer Screening Market Size and Forecast, by Cancer Type (2022-2029) 5.5.4.2. Italy Lung Cancer Screening Market Size and Forecast, by Diagnosis Type (2022-2029) 5.5.4.3. Italy Lung Cancer Screening Market Size and Forecast, by Age Group(2022-2029) 5.5.4.4. Italy Lung Cancer Screening Market Size and Forecast, by End-User (2022-2029) 5.5.5. Spain 5.5.5.1. Spain Lung Cancer Screening Market Size and Forecast, by Cancer Type (2022-2029) 5.5.5.2. Spain Lung Cancer Screening Market Size and Forecast, by Diagnosis Type (2022-2029) 5.5.5.3. Spain Lung Cancer Screening Market Size and Forecast, by Age Group (2022-2029) 5.5.5.4. Spain Lung Cancer Screening Market Size and Forecast, by End-User (2022-2029) 5.5.6. Sweden 5.5.6.1. Sweden Lung Cancer Screening Market Size and Forecast, by Cancer Type (2022-2029) 5.5.6.2. Sweden Lung Cancer Screening Market Size and Forecast, by Diagnosis Type (2022-2029) 5.5.6.3. Sweden Lung Cancer Screening Market Size and Forecast, by Age Group (2022-2029) 5.5.6.4. Sweden Lung Cancer Screening Market Size and Forecast, by End-User (2022-2029) 5.5.7. Austria 5.5.7.1. Austria Lung Cancer Screening Market Size and Forecast, by Cancer Type (2022-2029) 5.5.7.2. Austria Lung Cancer Screening Market Size and Forecast, by Diagnosis Type (2022-2029) 5.5.7.3. Austria Lung Cancer Screening Market Size and Forecast, by Age Group (2022-2029) 5.5.7.4. Austria Lung Cancer Screening Market Size and Forecast, by End-User (2022-2029) 5.5.8. Rest of Europe 5.5.8.1. Rest of Europe Lung Cancer Screening Market Size and Forecast, by Cancer Type (2022-2029) 5.5.8.2. Rest of Europe Lung Cancer Screening Market Size and Forecast, by Diagnosis Type (2022-2029) 5.5.8.3. Rest of Europe Lung Cancer Screening Market Size and Forecast, by Age Group (2022-2029) 5.5.8.4. Rest of Europe Lung Cancer Screening Market Size and Forecast, by End-User (2022-2029) 6. Asia Pacific Lung Cancer Screening Market Size and Forecast by Segmentation (by Value in USD Million) 2022-2029 6.1. Asia Pacific Lung Cancer Screening Market Size and Forecast, by Cancer Type (2022-2029) 6.2. Asia Pacific Lung Cancer Screening Market Size and Forecast, by Diagnosis Type (2022-2029) 6.3. Asia Pacific Lung Cancer Screening Market Size and Forecast, by Age Group (2022-2029) 6.4. Asia Pacific Lung Cancer Screening Market Size and Forecast, by End-User (2022-2029) 6.5. Asia Pacific Lung Cancer Screening Market Size and Forecast, by Country (2022-2029) 6.7.1. China 6.5.1.1. China Lung Cancer Screening Market Size and Forecast, by Cancer Type (2022-2029) 6.5.1.2. China Lung Cancer Screening Market Size and Forecast, by Diagnosis Type (2022-2029) 6.5.1.3. China Lung Cancer Screening Market Size and Forecast, by Age Group (2022-2029) 6.5.1.4. China Lung Cancer Screening Market Size and Forecast, by End-User (2022-2029) 6.5.2. S Korea 6.5.2.1. S Korea Lung Cancer Screening Market Size and Forecast, by Cancer Type (2022-2029) 6.5.2.2. S Korea Lung Cancer Screening Market Size and Forecast, by Diagnosis Type (2022-2029) 6.5.2.3. S Korea Lung Cancer Screening Market Size and Forecast, by Age Group (2022-2029) 6.5.2.4. S Korea Lung Cancer Screening Market Size and Forecast, by End-User (2022-2029) 6.5.3. Japan 6.5.3.1. Japan Lung Cancer Screening Market Size and Forecast, by Cancer Type (2022-2029) 6.5.3.2. Japan Lung Cancer Screening Market Size and Forecast, by Diagnosis Type (2022-2029) 6.5.3.3. Japan Lung Cancer Screening Market Size and Forecast, by Age Group (2022-2029) 6.5.3.4. Japan Lung Cancer Screening Market Size and Forecast, by End-User (2022-2029) 6.5.4. India 6.5.4.1. India Lung Cancer Screening Market Size and Forecast, by Cancer Type (2022-2029) 6.5.4.2. India Lung Cancer Screening Market Size and Forecast, by Diagnosis Type (2022-2029) 6.5.4.3. India Lung Cancer Screening Market Size and Forecast, by Age Group (2022-2029) 6.5.4.4. India Lung Cancer Screening Market Size and Forecast, by End-User (2022-2029) 6.5.5. Australia 6.5.5.1. Australia Lung Cancer Screening Market Size and Forecast, by Cancer Type (2022-2029) 6.5.5.2. Australia Lung Cancer Screening Market Size and Forecast, by Diagnosis Type (2022-2029) 6.5.5.3. Australia Lung Cancer Screening Market Size and Forecast, by Age Group (2022-2029) 6.5.5.4. Australia Lung Cancer Screening Market Size and Forecast, by End-User (2022-2029) 6.5.6. Indonesia 6.5.6.1. Indonesia Lung Cancer Screening Market Size and Forecast, by Cancer Type (2022-2029) 6.5.6.2. Indonesia Lung Cancer Screening Market Size and Forecast, by Diagnosis Type (2022-2029) 6.5.6.3. Indonesia Lung Cancer Screening Market Size and Forecast, by Age Group (2022-2029) 6.5.6.4. Indonesia Lung Cancer Screening Market Size and Forecast, by End-User (2022-2029) 6.5.7. Malaysia 6.5.7.1. Malaysia Lung Cancer Screening Market Size and Forecast, by Cancer Type (2022-2029) 6.5.7.2. Malaysia Lung Cancer Screening Market Size and Forecast, by Diagnosis Type (2022-2029) 6.5.7.3. Malaysia Lung Cancer Screening Market Size and Forecast, by Age Group (2022-2029) 6.5.7.4. Malaysia Lung Cancer Screening Market Size and Forecast, by End-User (2022-2029) 6.5.8. Vietnam 6.5.8.1. Vietnam Lung Cancer Screening Market Size and Forecast, by Cancer Type (2022-2029) 6.5.8.2. Vietnam Lung Cancer Screening Market Size and Forecast, by Diagnosis Type (2022-2029) 6.5.8.3. Vietnam Lung Cancer Screening Market Size and Forecast, by Age Group(2022-2029) 6.5.8.4. Vietnam Lung Cancer Screening Market Size and Forecast, by End-User (2022-2029) 6.5.9. Taiwan 6.5.9.1. Taiwan Lung Cancer Screening Market Size and Forecast, by Cancer Type (2022-2029) 6.5.9.2. Taiwan Lung Cancer Screening Market Size and Forecast, by Diagnosis Type (2022-2029) 6.5.9.3. Taiwan Lung Cancer Screening Market Size and Forecast, by Age Group (2022-2029) 6.5.9.4. Taiwan Lung Cancer Screening Market Size and Forecast, by End-User (2022-2029) 6.5.10. Rest of Asia Pacific 6.5.10.1. Rest of Asia Pacific Lung Cancer Screening Market Size and Forecast, by Cancer Type (2022-2029) 6.5.10.2. Rest of Asia Pacific Lung Cancer Screening Market Size and Forecast, by Diagnosis Type (2022-2029) 6.5.10.3. Rest of Asia Pacific Lung Cancer Screening Market Size and Forecast, by Age Group (2022-2029) 6.5.10.4. Rest of Asia Pacific Lung Cancer Screening Market Size and Forecast, by End-User (2022-2029) 7. Middle East and Africa Lung Cancer Screening Market Size and Forecast by Segmentation (by Value in USD Million) 2022-2029 7.1. Middle East and Africa Lung Cancer Screening Market Size and Forecast, by Cancer Type (2022-2029) 7.2. Middle East and Africa Lung Cancer Screening Market Size and Forecast, by Diagnosis Type (2022-2029) 7.3. Middle East and Africa Lung Cancer Screening Market Size and Forecast, by Age Group (2022-2029) 7.4. Middle East and Africa Lung Cancer Screening Market Size and Forecast, by End-User (2022-2029) 7.5. Middle East and Africa Lung Cancer Screening Market Size and Forecast, by Country (2022-2029) 7.5.1. South Africa 7.5.1.1. South Africa Lung Cancer Screening Market Size and Forecast, by Cancer Type (2022-2029) 7.5.1.2. South Africa Lung Cancer Screening Market Size and Forecast, by Diagnosis Type (2022-2029) 7.5.1.3. South Africa Lung Cancer Screening Market Size and Forecast, by Age Group (2022-2029) 7.5.1.4. South Africa Lung Cancer Screening Market Size and Forecast, by End-User (2022-2029) 7.5.2. GCC 7.5.2.1. GCC Lung Cancer Screening Market Size and Forecast, by Cancer Type (2022-2029) 7.5.2.2. GCC Lung Cancer Screening Market Size and Forecast, by Diagnosis Type (2022-2029) 7.5.2.3. GCC Lung Cancer Screening Market Size and Forecast, by Age Group (2022-2029) 7.5.2.4. GCC Lung Cancer Screening Market Size and Forecast, by End-User (2022-2029) 7.5.3. Nigeria 7.5.3.1. Nigeria Lung Cancer Screening Market Size and Forecast, by Cancer Type (2022-2029) 7.5.3.2. Nigeria Lung Cancer Screening Market Size and Forecast, by Diagnosis Type (2022-2029) 7.5.3.3. Nigeria Lung Cancer Screening Market Size and Forecast, by Age Group (2022-2029) 7.5.3.4. Nigeria Lung Cancer Screening Market Size and Forecast, by End-User (2022-2029) 7.5.4. Rest of ME&A 7.5.4.1. Rest of ME&A Lung Cancer Screening Market Size and Forecast, by Cancer Type (2022-2029) 7.5.4.2. Rest of ME&A Lung Cancer Screening Market Size and Forecast, by Diagnosis Type (2022-2029) 7.5.4.3. Rest of ME&A Lung Cancer Screening Market Size and Forecast, by Age Group (2022-2029) 7.5.4.4. Rest of ME&A Lung Cancer Screening Market Size and Forecast, by End-User (2022-2029) 8. South America Lung Cancer Screening Market Size and Forecast by Segmentation (by Value in USD Million) 2022-2029 8.1. South America Lung Cancer Screening Market Size and Forecast, by Cancer Type (2022-2029) 8.2. South America Lung Cancer Screening Market Size and Forecast, by Diagnosis Type (2022-2029) 8.3. South America Lung Cancer Screening Market Size and Forecast, by Age Group(2022-2029) 8.4. South America Lung Cancer Screening Market Size and Forecast, by End-User (2022-2029) 8.5. South America Lung Cancer Screening Market Size and Forecast, by Country (2022-2029) 8.5.1. Brazil 8.5.1.1. Brazil Lung Cancer Screening Market Size and Forecast, by Cancer Type (2022-2029) 8.5.1.2. Brazil Lung Cancer Screening Market Size and Forecast, by Diagnosis Type (2022-2029) 8.5.1.3. Brazil Lung Cancer Screening Market Size and Forecast, by Age Group (2022-2029) 8.5.1.4. Brazil Lung Cancer Screening Market Size and Forecast, by End-User (2022-2029) 8.5.2. Argentina 8.5.2.1. Argentina Lung Cancer Screening Market Size and Forecast, by Cancer Type (2022-2029) 8.5.2.2. Argentina Lung Cancer Screening Market Size and Forecast, by Diagnosis Type (2022-2029) 8.5.2.3. Argentina Lung Cancer Screening Market Size and Forecast, by Age Group (2022-2029) 8.5.2.4. Argentina Lung Cancer Screening Market Size and Forecast, by End-User (2022-2029) 8.5.3. Rest Of South America 8.5.3.1. Rest Of South America Lung Cancer Screening Market Size and Forecast, by Cancer Type (2022-2029) 8.5.3.2. Rest Of South America Lung Cancer Screening Market Size and Forecast, by Diagnosis Type (2022-2029) 8.5.3.3. Rest Of South America Lung Cancer Screening Market Size and Forecast, by Age Group (2022-2029) 8.5.3.4. Rest Of South America Lung Cancer Screening Market Size and Forecast, by End-User (2022-2029) 9. Global Lung Cancer Screening Market: Competitive Landscape 9.1. MMR Competition Matrix 9.2. Competitive Landscape 9.3. Key Players Benchmarking 9.3.1. Company Name 9.3.2. Business Segment 9.3.3. End-user Segment 9.3.4. Revenue (2022) 9.3.5. Company Locations 9.4. Leading Lung Cancer Screening Market Companies, by market capitalization 9.5. Market Structure 9.5.1. Market Leaders 9.5.2. Market Followers 9.5.3. Emerging Players 9.6. Mergers and Acquisitions Details 10. Company Profile: Key Players 10.1. GE Healthcare (United States) 10.1.1. Company Overview 10.1.2. Business Portfolio 10.1.3. Financial Overview 10.1.4. SWOT Analysis 10.1.5. Strategic Analysis 10.1.6. Scale of Operation (small, medium, and large) 10.1.7. Details on Partnership 10.1.8. Regulatory Accreditations and Certifications Received by Them 10.1.9. Awards Received by the Firm 10.1.10. Recent Developments 10.2. PenRad Technologies, Inc. (United States) 10.3. NanoString, Myriad Genetics Inc. (United States) 10.4. OncoCyte (United States) 10.5. Biodesix (United States) 10.6. Broncus (United States) 10.7. Abbott (United States) 10.8. Illumina, Inc., (United States) 10.9. Thermo Fischer Scientific (United States) 10.10. Medtronic (United States) 10.11. Nuance Communications, Inc. (United States) 10.12. Riverain Tech (United States) 10.13. 20/20 Gene Systems (United States) 10.14. Danaher Corporation (United States) 10.15. NeoGenomics (United States) 10.16. Eon Health (United States) 10.17. Siemens Healthineers AG (Germany) 10.18. Agilent Technologies, Inc., AstraZeneca (United Kingdom) 10.19. Insight Genetics (United Kingdom) 10.20. Inivata (United Kingdom) 10.21. Oncimmune (United Kingdom) 10.22. Koninklijke Philips N.V. (The Netherlands) 10.23. QIAGEN (The Netherlands) 10.24. Quest Diagnostics Incorporated (The Netherlands) 10.25. F. Hoffmann-La Roche Ltd. (Switzerland) 10.26. Janssen Pharmaceuticals, Inc. (Belgium) 10.27. Sanofi, (France) 10.28. Canon Medical Systems Corporation (Japan) 10.29. FUJIFILM Holdings Corporation (Japan) 10.30. VisionGate (India) 11. Key Findings 12. Industry Recommendations 13. Lung Cancer Screening Market: Research Methodology 14. Terms and Glossary